Compumedics achieves record revenues and profitability in FY24

Compumedics Limited (ASX:CMP) has reported record sales orders of $52m and shipped record revenues of $49.7m for FY24. The company achieved a full year FY24 profitability with EBITDA returning to profit at $2.5m, compared to a $2.0m loss in FY23. The growth was primarily driven by the new SaaS product offering, with ongoing investment in sales and marketing.

Executive Commentary on FY24 Performance and FY25 Outlook

The Company's return to EBITDA profitability in FY24 was largely due to the increase in sales, improved margins, and the decision to write back some of the intangible asset value associated with the MEG business. The Company anticipates revenues for FY25 to exceed $55m and EBITDA to be about $5m, driven primarily by the new SaaS product offering, which will necessitate ongoing investment in sales and marketing. The Company remains committed to its strategic growth plans, aiming to deliver stronger growth over the medium term.

Summary of FY24 Performance and FY25 Outlook

Compumedics achieved record sales orders and revenues in FY24, with a full year FY24 profitability. The company's growth was driven by the new SaaS product offering, resulting in increased sales and improved margins. The Company anticipates revenues for FY25 to exceed $55m and EBITDA to be about $5m, with a focus on the new SaaS product offering. Compumedics remains committed to its strategic growth plans, aiming to deliver stronger growth over the medium term.